gene. Also, mutations in IZKF3, which also had HIV integrations detected in two of our three participants, was recently associated with a form of acute lymphoblastic leukemia (35) . Fourth, as somatic mutations that "drive" cancers are estimated to only convey a 0.4% growth advantage (36) , HIV integration into genes with subtle enhancement of cell proliferation may be difficult to detect as clonal due to our limited sampling.
HIV-infected cells that express viral proteins are likely to be eliminated by immune surveillance, or virus replication may lead to cell lysis. Whether the proliferating and persisting HIV-infected cells that we describe harbor replication-competent virus is critical to defining their role in perpetuating the infectious virus reservoir. Undoubtedly, some clonal populations persist due to defects in expression of the proviral genome (9, 10, 37) . Although we did not evaluate viral sequences for replication competency, lethally hypermutated viral genomes were linked to three integration sites (Fig. 2) . However, cells producing viremias with identical env sequences have been shown to harbor replication-competent virus (38) . Also, approximately 12% of proviruses refractory to in vitro induction were found to have intact genomes and may be infectious (27) . Although transcriptional interference was not detected in the aforementioned noninduced viral transcripts (26, 27) , others have observed that the site of integration may cause transcriptional interference (34, (39) (40) (41) (42) (43) .
In conclusion, HIV integration into genes associated with cancer or cell cycle regulation appears to confer a survival advantage that allows these cells to persist during suppressive ART, with cell proliferation appearing to serve as an important mechanism of HIV persistence. To be defined are the mechanisms contributing to cell proliferation, the role of proliferating cells in perpetuating the infectious virus reservoir, and whether therapies that target HIV-infected proliferating cells, specific genes, or their products may contribute to a curative strategy for HIV infection.
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Many people around the world are coinfected with herpesviruses and intestinal helminths. Although herpesviruses can modulate immunity to harm or benefit the host (7) (8) (9) (10) (11) , the effects of helminth coinfection on chronic herpesvirus infection are unexplored. Intestinal helminths generate strong T helper 2 (T H 2)-driven cytokine responses, which counter the biological effects of IFNg and drive the activation of macrophages with an M2 (immunoregulatory) rather than M1 (proinflammatory) phenotype (12) . Parasitic worms may influence control of pathogens-including Mycobacterium tuberculosis, HIV, and Plasmodium species in humans-but there are few studies elucidating the mechanisms behind this immunomodulation (13) . Thus, we considered the hypothesis that parasite infection would induce MHV68 reactivation in vivo.
We examined the effects of acute infection with Heligmosomoides polygyrus or Schistosomiasis mansoni (Sm) egg administration on MHV68 reactivation from latency using a MHV68 virus expressing luciferase under the control of a lytic viral promoter upon reactivation from latency in vivo (MHV68-M3-FL) (14) . Both acute H. polygyrus infection and Sm egg challenge reactivated MHV68 infection (Fig. 1, A to D) . Mice latently infected for more than 100 days also showed increased luciferase expression after Sm egg challenge ( fig.  S1 ). By contrast, infection with the systemic bacteria Listeria monocytogenes did not stimulate viral reactivation (fig. S2) . Thus, responses to either a nematode parasite or trematode eggs induced herpesvirus reactivation, suggesting a role for T H 2 cytokines in viral reactivation. To determine whether T H 2 cytokines affect latently infected macrophages, we compared host gene expression patterns in virally infected and uninfected macrophages during chronic infection. We engineered MHV68 to express cre-recombinase (MHV68-cre) from a locus permitting heterologous gene expression without altering viral replication or reactivation (15) (fig. S3) Error bars indicate SEM. n.d. not detected; n.s. not significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by t test or one-way ANOVA with Sidak's multiple comparisons test.
virus-positive macrophages, whereas genes upregulated in M2 BMDMs were enriched in virusnegative cells ( Fig. 2A and table S1 ). This was consistent with the role of IFNg, which drives M1 macrophage polarization, in inhibiting MHV68 replication and reactivation (3, 4) . We therefore tested whether latent MHV68 infection was restricted to M1-type macrophages by infecting tdRFP mice carrying the Arginase-1 (Arg1)-YFP reporter (YARG, a marker for macrophages stimulated with T H 2 cytokines) (17) with MHV68-cre. Surprisingly, virus-positive macrophages were either positive or negative for Arg1 (Fig. 2, B and C) , suggesting that despite the role for IFNg in controlling chronic MHV68 infection, at least some virus-infected cells were exposed to cytokines that drive Arg-1 expression in vivo.
Along with the observation that T H 2 cytokineinducing parasites promote reactivation from latency, the presence of an IL-4 signature in some virus-infected macrophages suggests a role for IL-4 in viral infection. We tested this by determining the effect of IL-4 on MHV68 replication in BMDMs. Treatment with IL-4 increased Arg1 expression ( fig. S4A) , consistent with M2 polarization (18) . As expected, few infected BMDMs expressed lytic viral antigens upon MHV68 infection (19) . However, IL-4 pretreatment increased the number of BMDMs expressing viral proteins and enhanced viral replication (Fig. 3A and fig. S4 , B to D); it also increased infection of transformed RAW264.7 macrophages (fig. S4E ). Treatment with IL-4 after MHV68 infection increased viral replication ( fig. S4F ), indicating that IL-4 acts on replication rather than by increasing the number of infected cells. Enhancement of replication was dependent on the T H 2-associated transcription factor Stat6 (Fig. 3A) and occurred with IL-13 stimulation, another T H 2-associated cytokine that uses the IL-4 receptor a chain and signals via Stat6 (Fig. 3B and fig. S4, D and G) . The T H 2 cytokine IL-5, which does not signal through Stat6, did not promote MHV68 replication (Fig. 3B) .
After treatment with IL-4, the majority of infected cells did not express the M2 markers CD206 or Arg1 (Fig. 3A and fig. S4A ), suggesting that not all IL-4-induced changes in macrophage differentiation are required for enhanced MHV68 replication (20) . Etomoxir blocks IL-4-induced changes in fatty acid oxidation (21) and upregulation of CD206 ( fig. S5A ) but did not block enhancement of MHV68 replication by IL-4 (fig.  S5B) . Moreover, IL-4 enhanced replication in the absence of peroxisome proliferator-activated receptor g (PPARg) or ARG1, key proteins involved in M2 macrophage function, or inducible nitric oxide synthase, an essential protein in M1 macrophage function ( fig. S5, C to G) (20) . Importantly, IL-4 antagonized IFNg-mediated suppression of viral replication (Fig. 3C) (3) . Because Stat6 antagonizes Stat1 (22), we tested whether IL-4 promoted virus replication in the absence of Stat1. IL-4 increased virus replication in Stat1-deficient BMDMs (fig. S6) .
Previously, we found that IFNg-mediated suppression of viral replication was associated with inhibition of promoters driving expression of the essential viral latent-to-lytic switch gene (gene 50) (3, 23) . IL-4 antagonizes IFNg-mediated suppression of gene 50 transcription (Fig. 3D ). This effect was specific to the viral promoter because IL-4 did not block IFNg-mediated induction of Nos2, and IFNg did not inhibit IL-4-mediated induction of Arg1 and Relma/ Fizz1 (fig. S7) . Furthermore, IL-4 and IL-13 transactivated the gene 50 N4/N5 promoter (Fig. 3E) (24) , and IL-4 antagonized IFNg-mediated suppression of the N4/N5 promoter (Fig. 3F) . The effect of IL-4 on the N4/N5 promoter was diminished by mutation of two of four putative Stat-binding sites in the promoter (Fig. 3G and fig. S8 ). Further, chromatin immunoprecipitation (ChIP) experiments revealed that Stat6 bound to the N4/N5 promoter after IL-4 treatment of MHV68-infected cells (Fig. 3H) . Taken together, these data suggest that activated Stat6 induced by IL-4/IL-13 promotes viral replication by binding to and acting on a viral promoter to induce expression of gene 50.
These counterbalancing effects of IFNg and IL-4 on virus replication and viral promoter activity suggest a potential mechanism by which IL-4-inducing pathogens such as helminths promote reactivation. Therefore, we treated mice infected with MHV68-M3-FL virus with a blocking antibody to IFNg (anti-IFNg) (clone H22) (25) , an isotype control antibody (clone PIP), longlasting IL-4 complexes (IL-4c) (26) , or a combination of anti-IFNg and IL-4c. No reactivation was observed after treatment with anti-IFNg, IL-4c, or PIP alone, indicating that a single signal was insufficient to reactivate virus in vivo. However, robust reactivation was observed in mice that received a combination of IL-4c and anti-IFNg (Fig. 4, A and B, and fig. S9A ). We next assayed reactivation using an independent assay (27, 28) . Little or no preformed virus was detectable in tissues after treatment with PIP, IL-4c, or antiIFNg alone (27) , whereas treatment with IL-4c plus anti-IFNg increased infectious virus ( fig. S9 , B and C). Together, these data support a "twosignal" mechanism by which coinfections could induce reactivation via induction of IL-4 and inhibition of T H 1 responses (12) .
Increased reactivation after treatment with both IL-4c/anti-IFNg required Stat6 (Fig. 4C) . We did not test the role of Stat1 or the IFNg receptor because both are required to establish latency (6) . To assess whether the effects of helminth infection on MHV68 reactivation also required Stat6, we challenged MHV68-infected Stat6KO mice with H. polygyrus. We found that helminth infection did not reactivate MHV68 from latency in Stat6KO mice, further supporting a two-signal model for control of g-herpesvirus reactivation in vivo (Fig. 4D) .
Our results suggested a possible role for IL-4 in human g-herpesvirus reactivation. We therefore tested whether IL-4 could reactivate the human g-herpesvirus KSHV in the BCBL-1 human B cell lymphoma cell line. We found that treatment with IL-4 increased immediate early (RTA, ORF45, and ORF57) and late (ORF19) viral transcripts (29) (Fig. 4E) . RTA is the homolog in KSHV of MHV68 gene 50, and ORF45 and ORF57 are both transactivators, indicating a common role of IL-4 in regulating important viral transcriptional transactivators. Furthermore, IL-4 treatment of cells increased virus production (Fig. 4F) , indicating that IL-4 is capable of inducing reactivation of KSHV.
A notable aspect of herpesvirus infection is its permanence despite ongoing immunity combined with the capacity to reactivate and spread to new hosts. This work illuminates one potential mechanism by which a g-herpesvirus exhibits these two apparently disparate functions. Our data suggest that the virus evolved cytokineresponsive promoters to remain latent under some conditions (IFNg-dominant) and reactivate under other conditions (IL-4-dominant). In this setting, coinfection may govern the outcome of reactivation by changing the balance in IL-4 and IFNg, thus raising a potential issue with herpesvirus reactivation and proposed live helminth therapies (12) . Additionally, our data illustrate one potential mechanism by which helminths and other type 2 immune response-inducing parasites influence host control of another pathogen through M2 macrophage polarization (13) . The fact that viral promoters for an essential gene are responsive to host cytokines implies that the viral genome evolved to sense the infection status of the host. We speculate that a similar mechanism for IL-4-induced reactivation of KSHV could also be true. Although not extensively studied, seroprevalence to KSHV is associated with hookworm and other parasitic infections in Uganda (30) . Intriguingly, certain Burkitt's lymphoma cell lines are reported to express EBV transcripts in response to IL-4 (31) .
Although mouse studies are done in specific pathogen-free animals, our data suggest that there is added complexity when multiple pathogens infect the same host, particularly in situations where one pathogen has the capacity to respond to specific immune signals generated to another pathogen to regulate chronic infection. Previously, we showed that herpesvirus infection, a component of the mammalian virome (1), enhances resistance to some pathogens (7) . Here, we demonstrate the opposite effect: that coinfection regulates herpesvirus reactivation. These studies emphasize that the spectrum of immunity to chronic infection is a dynamic equilibrium regulated by coinfections, in part through highly evolved pathogen genomes with the capacity to sense host cytokines.
